{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T18:40:43Z","timestamp":1762800043209,"version":"build-2065373602"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Postoperative mortality following cardiac surgery remains high, highlighting the need to optimize perioperative medication strategies. Angiotensin-converting enzyme inhibitors (ACEIs) exert cardioprotective effects; however, the impact of their preoperative use on postoperative outcomes remains uncertain. This study evaluated the association between preoperative ACEI use and postoperative outcomes in cardiac surgery patients using a large dataset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients from the MIMIC-IV database, grouped by preoperative ACEI use and non-ACEI use. Primary outcomes included in-hospital mortality; secondary outcomes included 30-day, 90-day, and 1-year mortality. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between ACEI use and postoperative mortality. Subgroup analyses were used to assess discontinuation timing and lisinopril doses. Propensity score matching was used to control for confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 17,175 patients, 1,516 used ACEIs preoperatively. Cox modeling showed that preoperative ACEI use was significantly associated with reduced in-hospital mortality (HR 0.615; 95% CI 0.506\u20130.747; p\u2009&lt;\u20090.001) and 30- and 90-day mortality (p\u2009&lt;\u20090.05). Subgroup suggested a significant association between ACEI use and lower mortality in patients without malignancy. Continuing ACEIs on the day of surgery was associated with reduced in-hospital mortality, whereas discontinuation was associated with an attenuation of this beneficial association. A medium lisinopril dose (10\u201320\u2009mg) was associated with the most consistent reduction in postoperative mortality. Results persisted after propensity score matching (p\u2009&lt;\u20090.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Continuing preoperative ACEI use on the day of surgery was associated with significantly reduced postoperative mortality. Medium-dose lisinopril was associated with the most consistent reduction in postoperative mortality, although patients with malignancy may require individualized assessment. These findings suggest that evidence-based perioperative ACEI management may be beneficial and warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0334889","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T18:21:31Z","timestamp":1762798891000},"page":"e0334889","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of dose and discontinuation timing of preoperative ACE inhibitors on survival outcomes in cardiac surgery: A MIMIC-IV database analysis"],"prefix":"10.1371","volume":"20","author":[{"given":"Xiu","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqiang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0895-9849","authenticated-orcid":true,"given":"Xuemei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"5","key":"pone.0334889.ref001","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1213\/ANE.0b013e31820bfe8e","article-title":"Review article: high stakes and high risk: a focused qualitative review of hazards during cardiac surgery","volume":"112","author":"EA Martinez","year":"2011","journal-title":"Anesth Analg"},{"key":"pone.0334889.ref002","doi-asserted-by":"crossref","first-page":"106931","DOI":"10.1016\/j.ijsu.2022.106931","article-title":"Quality improvement program in Latin America decreases mortality after cardiac surgery: a before-after intervention study","volume":"106","author":"OAV Mejia","year":"2022","journal-title":"Int J Surg"},{"issue":"2","key":"pone.0334889.ref003","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.athoracsur.2020.05.104","article-title":"Postoperative Atrial Fibrillation After Cardiac Surgery: A Systematic Review and Meta-Analysis","volume":"111","author":"R Eikelboom","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"pone.0334889.ref004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejim.2023.01.005","article-title":"Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences?","volume":"110","author":"C Borghi","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"9","key":"pone.0334889.ref005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11886-020-01352-8","article-title":"Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?","volume":"22","author":"JM Turner","year":"2020","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"pone.0334889.ref006","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.mayocp.2022.06.036","article-title":"Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"97","author":"K Awad","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"pone.0334889.ref007","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/acsptsci.1c00269","article-title":"Evaluation of Antioxidant Therapeutic Value of ACE Inhibitor as Adjunct Therapy on Type 2 Diabetes Mellitus Patients with Cardiovascular Disease","volume":"5","author":"A Elfowiris","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"pone.0334889.ref008","doi-asserted-by":"crossref","first-page":"104302","DOI":"10.1016\/j.mvr.2021.104302","article-title":"Catalpol alleviates myocardial ischemia reperfusion injury by activating the Nrf2\/HO-1 signaling pathway","volume":"140","author":"H Ge","year":"2022","journal-title":"Microvasc Res"},{"issue":"11","key":"pone.0334889.ref009","article-title":"Captopril alleviates hypertension-induced renal damage, inflammation, and NF-\u03baB activation","volume":"51","author":"Z Gan","year":"2018","journal-title":"Braz J Med Biol Res"},{"issue":"7","key":"pone.0334889.ref010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003531","article-title":"Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability","volume":"5","author":"E Donnarumma","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"pone.0334889.ref011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/ijms20020239","article-title":"Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling","volume":"20","author":"T Sato","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"22","key":"pone.0334889.ref012","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1111\/bph.14489","article-title":"Angiotensin-converting enzyme inhibitor works as a scar formation inhibitor by down-regulating Smad and TGF-\u03b2-activated kinase 1 (TAK1) pathways in mice","volume":"175","author":"W-Q Tan","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"1","key":"pone.0334889.ref013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/ALN.0000000000001404","article-title":"Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort","volume":"126","author":"PS Roshanov","year":"2017","journal-title":"Anesthesiology"},{"key":"pone.0334889.ref014","doi-asserted-by":"crossref","first-page":"111401","DOI":"10.1016\/j.jclinane.2024.111401","article-title":"Effect of continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers on the day of surgery on myocardial injury after non-cardiac surgery: A retrospective cohort study","volume":"94","author":"J Kim","year":"2024","journal-title":"J Clin Anesth"},{"issue":"10","key":"pone.0334889.ref015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.12788\/jhm.3036","article-title":"Prospective Randomized Evaluation of Preoperative Angiotensin-Converting Enzyme Inhibition (PREOP-ACEI)","volume":"13","author":"JF Shiffermiller","year":"2018","journal-title":"J Hosp Med"},{"issue":"1","key":"pone.0334889.ref016","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/FJC.0000000000001491","article-title":"Prior Use of Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers and Clinical Outcomes of Sepsis and Septic Shock: A Systematic Review and Meta-analysis","volume":"83","author":"DB Shrestha","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"pone.0334889.ref017","article-title":"Perioperative Renin-Angiotensin System Inhibitors Improve Major Outcomes of Heart Failure Patients Undergoing Cardiac Surgery: A Propensity-Adjusted Cohort Study","volume":"277","author":"Y-Q Zhang","year":"2023","journal-title":"Ann Surg"},{"issue":"1","key":"pone.0334889.ref018","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.athoracsur.2016.10.021","article-title":"Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome","volume":"104","author":"MW Manning","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"pone.0334889.ref019","doi-asserted-by":"crossref","first-page":"207","DOI":"10.31083\/j.rcm.2021.01.288","article-title":"Antecedent ACE-inhibition, inflammatory response, and cardiac surgery associated acute kidney injury","volume":"22","author":"P Presta","year":"2021","journal-title":"Rev Cardiovasc Med"},{"issue":"17","key":"pone.0334889.ref020","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.3390\/ijms25179247","article-title":"Inhibitors of NLRP3 Inflammasome Formation: A Cardioprotective Role for the Gasotransmitters Carbon Monoxide, Nitric Oxide, and Hydrogen Sulphide in Acute Myocardial Infarction","volume":"25","author":"FM Payne","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0334889.ref021","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12964-023-01087-3","article-title":"P38 MAPK activated ADAM17 mediates ACE2 shedding and promotes cardiac remodeling and heart failure after myocardial infarction","volume":"21","author":"Q Chen","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"13","key":"pone.0334889.ref022","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/eurheartj\/ehad716","article-title":"Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial","volume":"45","author":"GL Ackland","year":"2024","journal-title":"Eur Heart J"},{"issue":"9","key":"pone.0334889.ref023","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/anae.16308","article-title":"The association of withholding or continuing angiotensin-converting enzyme inhibitors or angiotensin 2 receptor blockers on acute kidney injury after non-cardiac surgery","volume":"79","author":"J Choi","year":"2024","journal-title":"Anaesthesia"},{"issue":"4","key":"pone.0334889.ref024","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bja.2025.06.026","article-title":"Perioperative management of renin-angiotensin system inhibitors in patients undergoing elective major noncardiac surgery: a mixed model investigation using systematic review, meta-analysis, multicentre service evaluation, and national survey","volume":"135","author":"E Giannas","year":"2025","journal-title":"Br J Anaesth"},{"issue":"12","key":"pone.0334889.ref025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2024.17123","article-title":"Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial","volume":"332","author":"M Legrand","year":"2024","journal-title":"JAMA"},{"key":"pone.0334889.ref026","doi-asserted-by":"crossref","first-page":"1343647","DOI":"10.3389\/fphar.2024.1343647","article-title":"Pre-operative maintenance of angiotensin-converting enzyme inhibitors is not associated with acute kidney injury in cardiac surgery patients with cardio-pulmonary bypass: a propensity-matched multicentric analysis","volume":"15","author":"P Guilleminot","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"pone.0334889.ref027","first-page":"313","article-title":"Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system","volume":"33","author":"T Eskelinen","year":"2022","journal-title":"Cancer Causes Control"},{"issue":"5","key":"pone.0334889.ref028","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate","volume":"180","author":"Y Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"2","key":"pone.0334889.ref029","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00246-023-03373-w","article-title":"Bransetter JW, Anderson M, Zaki H, Gleason ME, Beshish AG. Captopril to Lisinopril Conversion in Pediatric Cardiothoracic Surgery Patients Less Than 7 Years of Age (RISE-7","volume":"45","year":"2024","journal-title":"). Pediatr Cardiol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T18:21:37Z","timestamp":1762798897000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334889"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"Lionetti","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0334889","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}